Literature DB >> 28195234

Targeted therapy: Leveraging ADCC to enhance anti-HER2 therapy.

David Killock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28195234     DOI： 10.1038/nrclinonc.2017.19

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.

Authors:  Y J Bang; G Giaccone; S A Im; D Y Oh; T M Bauer; J L Nordstrom; H Li; G R Chichili; P A Moore; S Hong; S J Stewart; J E Baughman; R J Lechleider; H A Burris
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976
  1 in total
  1 in total

1.  Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.

Authors:  Daniel V T Catenacci; Stephanie Moya; Samantha Lomnicki; Leah M Chase; Bryan F Peterson; Natalie Reizine; Lindsay Alpert; Namrata Setia; Shu-Yuan Xiao; John Hart; Uzma D Siddiqui; D Kyle Hogarth; Oliver S Eng; Kiran Turaga; Kevin Roggin; Mitchell C Posner; Paul Chang; Sunil Narula; Murtuza Rampurwala; Yuan Ji; Theodore Karrison; Chih-Yi Liao; Blase N Polite; Hedy L Kindler
Journal:  Cancer Discov       Date:  2020-11-24       Impact factor: 39.397
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.